KEYNOTE-671 围手术期帕博利珠单抗治疗早期 NSCLC 的五年结局
KEYNOTE-671 是一项随机 III 期研究,797 例可切除 II、IIIA 或 IIIB(N2)期 NSCLC 患者随机接受围手术期帕博利珠单抗或安慰剂联合新辅助化疗。中位随访 60.4 个月时,帕博利珠单抗组 5 年 EFS 为 49.9% 对 26.5%(HR 0.58),5 年 OS 为 64.6% 对 53.6%(HR 0.74),支持该方案作为可切除早期 NSCLC 的标准治疗。
要点
- 围手术期帕博利珠单抗使 5 年 EFS 近乎翻倍(49.9% 对 26.5%,HR 0.58)。
- 5 年 OS 持续改善(64.6% 对 53.6%,HR 0.74)。
- 长期随访未发现健康相关生活质量受损,安全性谱与已知一致。
核心结论
- 随访 5 年后,围手术期帕博利珠单抗联合新辅助化疗较新辅助化疗加手术 alone 使 EFS 近乎翻倍并持续改善 OS。
- 观察到的持久且具有临床意义的获益支持该方案作为可切除早期 NSCLC 患者的标准治疗。
研究设计与样本
- III 期随机 KEYNOTE-671 研究,纳入既往未治疗、可切除 II、IIIA 或 IIIB(N2)期 NSCLC 患者。
- 797 例患者按 1:1 随机分配至帕博利珠单抗组(n=397)或安慰剂组(n=400)。
- 方案为 4 周期帕博利珠单抗 200 mg 或安慰剂每 3 周联合铂类双药化疗,手术后辅助帕博利珠单抗或安慰剂每 3 周最多 13 周期。
- 双主要终点为研究者按 RECIST v1.1 评估的 EFS 和 OS。
- 随机至数据截止(2025 年 7 月 3 日)的中位时间为 60.4 个月(范围 42.6–85.8)。
主要发现
- 帕博利珠单抗组 5 年 EFS 为 49.9%(95% CI 44.6–55.0),安慰剂组为 26.5%(95% CI 21.7–31.5),HR 0.58(95% CI 0.48–0.69)。
- 帕博利珠单抗组 5 年 OS 为 64.6%(95% CI 59.5–69.2),安慰剂组为 53.6%(95% CI 48.3–58.6),HR 0.74(95% CI 0.59–0.92)。
- 更长随访中,帕博利珠单抗组较安慰剂组未发现健康相关生活质量受损。
- 安全性情况与各治疗已知特征一致。
临床怎么用
- 对于可切除 II、IIIA 或 IIIB(N2)期 NSCLC,可考虑围手术期帕博利珠单抗联合新辅助化疗及术后辅助帕博利珠单抗。
- 该 5 年随访数据支持将围手术期帕博利珠单抗方案作为可切除早期 NSCLC 的标准治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved survival outcomes compared with neoadjuvant chemotherapy and surgery alone in participants with early-stage non-small-cell lung cancer (NSCLC) in the phase 3, randomized KEYNOTE-671 study. We report results from KEYNOTE-671 after 5 years of follow-up. PATIENTS AND METHODS: Eligible participants with previously untreated, resectable stage II, IIIA, or IIIB (N2) NSCLC were randomized 1:1 to 4 cycles of pembrolizumab 200 mg or placebo every 3 weeks, plus platinum-doublet chemotherapy, followed by surgery then adjuvant pembrolizumab or placebo every 3 weeks for up to 13 cycles. Dual primary endpoints were event-free survival (EFS) per RECIST v1.1 by investigator assessment and overall survival (OS). RESULTS: 797 participants were randomized to pembrolizumab (n=397) or placebo (n=400). Median time from randomization to data cutoff (July 3, 2025) was 60.4 (range, 42.6‒85.8) months. Five-year EFS was 49.9% (95% CI, 44.6‒55.0) in the pembrolizumab arm and 26.5% (95% CI, 21.7‒31.5) in the placebo arm (HR, 0.58; 95% CI, 0.48‒0.69); 5-year OS was 64.6% (95% CI, 59.5‒69.2) and 53.6% (95% CI, 48.3‒58.6), respectively (HR, 0.74; 95% CI, 0.59‒0.92). No detriment to health-related quality of life was identified in the pembrolizumab versus placebo arm with longer follow-up. Safety was consistent with the known profiles of each treatment. CONCLUSIONS: After 5 years of follow-up, EFS was nearly double with perioperative pembrolizumab plus neoadjuvant chemotherapy, along with continued improvement in OS compared with neoadjuvant chemotherapy and surgery alone. The durable and clinically meaningful benefits observed support use of this treatment as a standard of care for patients with resectable early-stage NSCLC (ClinicalTrials.gov, NCT03425643).
引用
- Wakelee H, Spicer JD, Gao S, et al. Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study. Ann Oncol. 2026. PMID: 42628840. doi:10.1016/j.annonc.2026.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。